

1625

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Docket No.

PG3602USW

Applicant(s): Campbell et al.

OCT 03 2001  
Serial No.  
09/838,836

Filing Date  
May 1, 2001

Examiner  
B. Robinson

Group Art Unit  
1625

PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

RECEIVED

OCT 05 2001

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

TECH CENTER 1600/2900

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED


	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	0 -	11 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	5 -	5 =	0 x	\$80.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

- ☒ No additional fee is required for amendment.
- ☐ Please charge Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_  
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392  
A duplicate copy of this sheet is enclosed.
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.

  
Signature

Dated: 9/28/01

I certify that this document and fee is being deposited on 9/28/01 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Signature of Person Mailing Correspondence

Cynthia M. Edwards

Typed or Printed Name of Person Mailing Correspondence

CC:

PG3602USW



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application: I. Campbell et al.

Serial No.: 09/830,836

Examiner: B. Robinson

Filing Date: 1 May 2001

Art Unit: 1625

For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

#6  
Chen  
10/12/01Commissioner of Patents  
Washington D.C. 20231RESPONSE TO RESTRICTION REQUIREMENT

Sir:

Responsive to the Office Action mailed 28 August 2001, please reconsider the instant application in view of the following remarks.

Remarks

Currently Claims 1-10, 13-14 and 17-35 are pending.

All Claims are subject to the Examiner's restriction requirement. The Office Action indicates that Applicants are entitled to examination of Examiner's group I together with one method of use claim to be selected from Examiner's groups III, IV, V, VI, VII, and VIII and one process claim to be selected from Examiner's groups II, IX, X and XI. Applicants respectfully traverse the restriction requirement.

The Examiner's restriction requirement does not account for claims 18, 19 and 20. A proper restriction requirement must account for all pending claims.

Applicants respectfully submit that 37 CFR 1.499(b) states that in national stage applications containing different categories of claims, unity of invention will exist if the claims are drawn to certain specified combinations, including a product, a process